Everything below concerns GLP-1 receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-29. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
== See also == Interactome Protein–protein interaction Protein function prediction Protein structure prediction Protein structure prediction software Gene prediction Macromolecular docking Protein–DNA interaction site predictor Two-hybrid screening FastContact
With 21 successful stolen bases in 28 attempts, it was his first season in the 20–20 club, that is, to steal 20 bases while hitting 20 home runs in the same season. Bagwell reached base 324 total times and in all but 11 games. He led the NL in doubles with 48 while earning his second All-Star selection and finishing ninth in the MVP voting. Rumors had surfaced during the 1996 season that manager Terry Collins did not get along well with Bagwell and Biggio, largely contributing to his dismissal. The Astros hired team color commentator Larry Dierker after the season to replace him. According to his autobiography, This Ain't Brain Surgery, Dierker was asked during the interview how he would handle the players. His response: "'Look, I'm tired of this Bagwell and Biggio s---,' I said. 'Bagwell and Biggio will not be a problem, believe me.' I now believe that this statement is the one that got me the job." The Astros won division titles in four of five seasons with Dierker as manager; however, in each instance, they did not advance past the first round of the playoffs, and 2001 was Dierker's last season as the club's manager.
A 2012 study published in the Skeptical Inquirer examined the grants and awards funded by NCCIH from 2000 to 2011, which totaled $1.3 billion. The study found no discoveries in complementary and alternative medicine that would justify the existence of this center. The authors argued that after 20 years and an expenditure of $2 billion, the failure of NCCIH was evidenced by the lack of publications and the failure to report clinical trials in peer-reviewed medical journals. They recommended that NCCIH be defunded or abolished and the concept of funding alternative medicine be discontinued. In 2019, an analysis by the Center for Inquiry found that NCCIH was continuing to fund questionable science and that "there is little hope of reforming the NCCIH as it is currently incorporated". It concluded that "There is no legitimate function that the NCCIH can serve that could not be better carried out by other existing organizations within the NIH umbrella." Writing for Quackwatch in 2023, William London criticized the NCCIH and its article "6 Things To Know When Selecting a Complementary Health Practitioner" for "misleading consumers" and promoting—rather than warning against—complementary health, which "is often a euphemism for quackery."
In botany, apical dominance is the phenomenon whereby the main, central stem of the plant is dominant over (i.e., grows more strongly than) other side stems; on a branch the main stem of the branch is further dominant over its own side twigs. Plant physiology describes apical dominance as the control exerted by the terminal bud (and shoot apex) over the outgrowth of lateral buds.
Sources: en.wikipedia.org
Additionally, the FDA has raised concerns over the lack of data to determine if the long-acting once-weekly version of exenatide (but not the twice-daily form of exenatide) may increase thyroid cancer risk. This concern comes out of observing a very small but nevertheless increased risk of thyroid cancer in rodents that was observed for another drug (liraglutide) that is in the same class as exenatide. The data available for exenatide showed less of a risk towards thyroid cancer than liraglutide, but to better quantify the risk the FDA has required Amylin to conduct additional rodent studies to better identify the thyroid issue. The approved form of the once weekly exenatide [Bydureon] has a black box warning discussing the thyroid issue. Eli Lilly has reported they have not seen a link in humans, but that it cannot be ruled out. Eli Lilly has stated the drug causes an increase in thyroid problems in rats given high doses. In March 2013, the FDA issued a Drug Safety Communication announcing investigations into incretin mimetics due to findings by academic researchers. A few weeks later, the European Medicines Agency launched a similar investigation into GLP-1 agonists and DPP-4 inhibitors.
== Lifestyle and nutrition == Regular physical activity, particularly weight-bearing and resistance exercises, has been shown to improve bone density and reduce the likelihood of fractures. While placing weight-bearing stress on these bones, it will signal the body to start strengthening and it will help stimulate bone growth to make the bones stronger over time. Adequate intake of calcium and vitamin D is essential for bone health. The National Osteoporosis Foundation recommends a daily calcium intake of 1,000 mg for men aged 50-70 and 1,200 mg for women aged 51 and older and men aged 71 and older. For vitamin D, a daily intake of 800-1,000 IU is recommended for adults aged 50 and older.
Pentagon Papers, Chapter 2 Archived 2011-08-06 at the Wayback Machine Vietnam: The Impossible War Fall, Bernard B. Street Without Joy: The French Debacle In Indochina ANAPI's official website (National Association of Former POWs in Indochina) Hanoi upon the army's return in victory (bicycles demystified) Viet Nam Portal Photos about the First War of Indochina (French Defense Archives) (ECPAD) (in French)
Sources: en.wikipedia.org
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
=== Discontinued === 1-Amino-5-bromouracil (ABU) – undefined mechanism of action [60] ABT-418 – nicotinic acetylcholine receptor agonist [61] ABT-436 – vasopressin V1B receptor antagonist [62] Adipiplon (NG-273) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [63] Alnespirone (S-20499) – serotonin 5-HT1A receptor agonist [64] Alosetron (GR-68755; GR-68755C; Lotronex) – serotonin 5-HT3 receptor antagonist [65] Alpidem (Ananxyl; S-800342-001; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [66] Alprazolam lingual spray – GABAA receptor positive allosteric modulator and benzodiazepine [67] AN-788 (IP-2018; NSD788) – serotonin–dopamine reuptake inhibitor (SDRI) [68] AP-521 – serotonin 5-HT1A receptor partial agonist [69] Aprepitant (Emend; L-754030; MK-0869; MK-869; ONO-7436) – neurokinin NK1 receptor antagonist [70] AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist [71] AVN-397 – undefined mechanism of action [72] AZD-2327 – δ-opioid receptor (DOR) agonist [73] AZD-8129 (AR-A000002; AR-A2XX; AR-A2) – serotonin 5-HT1B receptor antagonist [74] Befloxatone (MD-370503) – reversible inhibitor of monoamine oxidase A (RIMA) [75] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [76] Bretazenil (RO-166028) – GABAA receptor positive allosteric modulator and benzodiazepine [77] Brofaromine (Brofaremine; CGP-11305A; Consonar; Consonev) – reversible inhibitor of monoamine oxidase A (RIMA) and serotonin reuptake inhibitor (SRI) [78] Buspirone transdermal (BuSpar Patch) – serotonin 5-HT1A receptor partial agonist and other actions [79] CGS-12066 – serotonin 5-HT1B receptor partial agonist and other actions [80] Coluracetam (BCI-540; MKC-231) – ionotropic glutamate AMPA receptor positive allosteric modulator, choline uptake and acetylcholine synthesis enhancer, and racetam [81] DAA-1097 – translocator protein (TSPO) agonist [82] Devazepide (Devacade; L-364718; MK-329) – Cholecystokinin A (CCKA) receptor antagonist [83] Dipraglurant (ADX-48621; mGluR5-NAM) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [84] Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [85] Emapunil (AC-5216; XBD173) – translocator protein (TSPO) agonist [86] Emicerfont (GW-876008; GW876008) – corticotropin releasing factor CRF1 receptor antagonist [87] Enciprazine (D-3112; WY-48624) – serotonin 5-HT1A receptor agonist and α1-adrenergic receptor ligand [88] Eplivanserin (Ciltyri; Sliwens; SR-46349; SR-46349B; SR-46615A) – serotonin 5-HT2A receptor antagonist [89] Eptapirone (F-11440) – serotonin 5-HT1A receptor agonist [90] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) [91] Flesinoxan (DU-29373) – serotonin 5-HT1A receptor agonist [92] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [93] Girisopam (EGIS-5810; GYKI-51189) – GABAA receptor positive allosteric modulator and benzodiazepine [94] GT-2203 – histamine H3 receptor agonist [95] Guanfacine (Guanfacine Carrier Wave project; SPD-554) – α2-adrenergic receptor agonist [96] Ipsapirone (BAY-Q-7821; TVX-Q-7821) – serotonin 5-HT1A receptor partial agonist [97] Isamoltane (CGP-361A) – beta blocker (β-adrenergic receptor antagonist) and serotonin 5-HT1A and 5-HT1B receptor antagonist [98] Itasetron (DAU-6215; U-98079) – serotonin 5-HT3 receptor antagonist [99] ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, and μ-opioid receptor (MOR) partial agonist [100] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor CRF1 receptor antagonist [101] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) ligand [102] Lorazepam intranasal – GABAA receptor positive allosteric modulator and benzodiazepine [103] Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist [104] Midazolam intranasal (ITI-111; midazolam nasal spray; Nayzilam; USL-261) – GABAA receptor positive allosteric modulator and benzodiazepine [105] MK-0777 (L-830982; TPA-023) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/triazolopyridazine [106] NBI-34041 (SB-723620) – corticotropin-releasing hormone (CRH) inhibitor [107] Nerisopam (EGIS-6775; GYKI-52322) – GABAA receptor positive allosteric modulator and benzodiazepine [108] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist [109] NS-11821 (NS11821) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [110] Orvepitant (GW-823296; GW823296X) – neurokinin NK1 receptor antagonist [111] Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [112] Panadiplon (FD-10571; FG-10571; NNC-140571; U-78875) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [113] Pazinaclone (A-77000; DN-2327) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [114] Pozanicline (A-87089.0; ABT-089) – nicotinic acetylcholine receptor agonist [115] Psilocybin (CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen [116] Research programme: depression and anxiety therapies - Roche/Vernalis – undefined mechanism of action [117] Research programme: GPCR modulators - Nxera Pharma – various actions [118] Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma – monoamine oxidase A (MAO-A) inhibitors [119] Ritanserin (R-55667) – serotonin 5-HT2 receptor antagonist and other actions [120] Robalzotan (AZD-7371; NAD-299) – serotonin 5-HT1A receptor antagonist [121] RS-127445 (MT-500) – serotonin 5-HT2B receptor antagonist [122] SAX-187 (WAY-181187) – serotonin 5-HT6 receptor agonist [123] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist [124] Siramesine (LU-28179) – sigma σ2 receptor agonist [125] SKL-PSY (FZ-016) – serotonin 5-HT1A receptor agonist [126] SSR-241586 (SSR241586) – neurokinin NK2 and NK3 receptor antagonist [127] SUN-8399 – serotonin 5-HT1A receptor agonist [128] Suriclone (RP-31264) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [129] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [130] Tiagabine (A-70569; CEP-6671; Gabitril; NO-050328; NO-328) – GABA transporter 1 (GAT-1) blocker and GABA reuptake inhibitor Troriluzole (BHV-4157; Dazluma; FC-4157; trigriluzole) – various actions (riluzole prodrug) [131] Vestipitant (GW-597599) – neurokinin NK1 receptor antagonist [132] Zabaglurant (TMP-301; TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [133] Zalospirone (WY-47846) – serotonin 5-HT1A receptor agonist [134]
Inflammatory back pain:Chronic, inflammatory back pain is defined when at least four out of five of the following parameters are present: (1) Age of onset below 40 years old, (2) insidious onset, (3) improvement with exercise, (4) no improvement with rest, and (5) pain at night (with improvement upon getting up). Pain often subsides as the day progresses with movement being of importance to alleviate the joint stiffness. Past history of inflammation in the joints, heels, or tendon-bone attachments Family history for axial spondyloarthritis or other associated rheumatic/autoimmune conditions Positive for the biomarker HLA-B27 Good response to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) Signs of elevated inflammation (C-reactive protein and erythrocyte sedimentation rate) Manifestation of psoriasis, inflammatory bowel disease, or inflammation of the eye (uveitis) If these criteria still do not give a compelling diagnosis magnetic resonance imaging (MRI) may be useful. MRI can show inflammation of the sacroiliac joint.
== Chemistry == Ampicillin sodium is derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Its chemical name is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. It has a molecular weight of 371.39 grams and its chemical formula is C16H18N3NaO4S. Sulbactam sodium is also a derivative of 6-aminopenicillanic acid. Chemically, it is known as either sodium penicillinate sulfone or sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide. It has a molecular weight of 255.22 grams and its chemical formula is C8H10NNaO5S.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
Different techniques detect different classes of impurities, so a single number does not describe a sample completely. Reversed-phase chromatography resolves related peptides well but can miss inorganic salts, while mass spectrometry confirms mass without quantifying everything present. Comparing results requires knowing which method was used and how it was validated.